Success Metrics

Clinical Success Rate
100.0%

Based on 17 completed trials

Completion Rate
100%(17/17)
Active Trials
1(6%)
Results Posted
100%(17 trials)

Phase Distribution

Ph phase_1
14
78%
Ph phase_2
2
11%
Ph phase_3
2
11%

Phase Distribution

14

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
14(77.8%)
Phase 2Efficacy & side effects
2(11.1%)
Phase 3Large-scale testing
2(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

17 of 17 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

18

all time

Status Distribution
Active(1)
Completed(17)

Detailed Status

Completed17
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 114 (77.8%)
Phase 22 (11.1%)
Phase 32 (11.1%)

Trials by Status

completed1794%
recruiting16%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT06241560Phase 2

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

Recruiting
NCT05321082Phase 3

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Completed
NCT06070610Phase 1

A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood

Completed
NCT06415045Phase 1

A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food

Completed
NCT05550636Phase 1

A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood

Completed
NCT06408870Phase 1

A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body

Completed
NCT05718648Phase 1

A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems

Completed
NCT03422068Phase 1

This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.

Completed
NCT05707403Phase 1

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

Completed
NCT03302078Phase 1

Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects

Completed
NCT05633862Phase 1

A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body

Completed
NCT05661344Phase 1

A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems

Completed
NCT06107036Phase 1

A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities

Completed
NCT03403439Phase 1

This Study in Healthy Men Tests How Itraconazole Influences the Amount of BI 1015550 in the Blood

Completed
NCT05321069Phase 3

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Completed
NCT04419506Phase 2

A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Completed
NCT01835899Phase 1

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution

Completed
NCT01594515Phase 1

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers

Completed

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18